The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response
Open accessAbstract
Clear cell renal cell carcinoma (ccRCC) has a high metastatic rate, and its incidence and mortality are still rising. The aim of this study was to identify the key tumor-infiltrating immune cells (TIICs) affecting the distant metastasis and prognosis of patients with ccRCC and to construct a relevant prognostic panel to predict immunotherapy response. Based on ccRCC bulk RNA sequencing data, resting mast cells (RMCs) were screened and verified using the CIBERSORT algorithm, survival analysis, and expression analysis. Distant metastasis-associated genes were identified using single-cell RNA sequencing data. Subsequently, a three-gene (CFB, PPP1R18, and TOM1L1) panel with superior distant metastatic and prognostic performance was established and validated, which stratified patients into high- and low-risk groups. The high-risk group exhibited lower infiltration of RMCs, higher tumor mutation burden (TMB), and worse prognosis. Therapeutically, the high-risk group was more sensitive to anti-PD-1 and anti-CTLA-4 immunotherapy, whereas the low-risk group displayed a better response to anti-PD-L1 immunotherapy. Furthermore, two immune clusters revealing distinct immune, clinical, and prognosis heterogeneity were distinguished. Immunohistochemistry of ccRCC samples verified the expression patterns of the three key genes. Collectively, the prognostic panel based on RMCs is able to predict distant metastasis and immunotherapy response in patients with ccRCC, providing new insight for the treatment of advanced ccRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggest that PPP1R18 likely functions as an oncogene associated with poor prognosis in ccRCC”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“The R package “DEseq2” [21] was used to screen DEGs between ccRCC and normal kidney samples.”
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · cited 1×
“Transcriptome counts were normalized using the R package “limma” [20], and the gene expression values from TCGA and ICGC datasets were transformed as log2 (x + 1) counts.”
MethodclusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611 · cited 1×
“org, accessed on 23 June 2022), a comprehensive database that plays an important role in the annotation and visualization of the gene list, was used for pathway analysis and protein–protein interaction (PPI) analysis [24].”
MethodRobust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“To explore the underlying effect of our model on the immune escape of ccRCC cells, we assessed the relationship between the RMC-based signature and ten immune checkpoints [61].”
MethodType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Among these noncancer cells in the TME, tumor-infiltrating immune cells (TIICs) play a central role in predicting the metastasis and mortality of various tumors [12].”
BackgroundTIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,913
Cited by
Zhu, Z., Jin, Y., Zhou, J., Chen, F., Chen, M., Gao, Z., Hu, L., Xuan, J., Li, X., Song, Z., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02059-y · Cited by 99
“Although the high-risk group shows lower infiltration of RMCs, higher tumor mutation burden (TMB), and worse prognosis, they are more sensitive to immune therapy with anti-PD1 and anti-CTLA-4, while the low-risk group responds better to immune therapy with anti-PD-L1 [44].”
BackgroundMethodSelf-citationPredicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes
Cheng, G., Zhou, Z., Li, S., Yang, S., Wang, Y., Ye, Z., & Ren, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-61302-0 · Cited by 14
“Prognostic differences between different risk subgroups are often driven by underlying molecular mechanisms and pathways 39,40 .”
Owoicho, A. M., Ogenyi, D. O., Zhilenkova, A. V., Essogmo, F. E., Tchawe, Y. S. N., Uchendu, I. K., Pascal, A. M., Nikitina, N. M., Rusanov, A. S., Sanikovich, V. D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010265 · Cited by 15
Tomita, Y., Motzer, R. J., Choueiri, T. K., Rini, B. I., Miyake, H., Oya, M., Albiges, L. K., Aizawa, M., Umeyama, Y., Wang, J., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102034 · Cited by 10
SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis in breast cancer
Zhang, D., Fang, J., Shan, J., Xu, L., Wu, Y., Lu, B., Zhang, X., Wang, C., Sun, P., & Wang, Q. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07401-y · Cited by 7
“TME plays an essential role in breast cancer development [21], and TIICs are instrumental in disease progression and patient prognosis for various malignancies [22].”
Metadata
- Authors
- Su, Y., Zhang, T., Lu, J., Qian, L., Fei, Y., Zhang, L., Fan, S., Zhou, J., Tang, J., Chen, H., & Liang, C.
- Affiliations
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, China
- Shanghai Jiao Tong University (CN)
- University of Oxford (GB)
- Anhui Medical University (CN)
- Corresponding author
- Chen, Haige
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-01-01
- Volume
- 12
- Issue
- 1
- Pages
- 180
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9818872
- OpenAlex
- W4313472298
- Cited by
- 20
- References
- 64
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 4
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Anhui Medical University Basic and Clinical Cooperative Research Promotion Project (2020xkjT031, 202110366035, 2017ZHYX02)
- National Level Innovation Training Program for Chinese College Students of the Ministry of Education of the People’s Republic of China (2020xkjT031, 202110366035, 2017ZHYX02)
- Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province (2020xkjT031, 202110366035, 2017ZHYX02)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- clear cell renal cell carcinoma, resting mast cells, distant metastasis, prognostic gene panel, immunotherapy response prediction, tumor-infiltrating immune cells, CFB, tumor mutational burden, anti-PD-1, anti-CTLA-4, PD-L1 inhibitors, immune heterogeneity, risk stratification
- MeSH terms
- Carcinoma, Carcinoma, Renal Cell, Humans, Immunotherapy, Kidney Neoplasms, Mast Cells, Prognosis, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response. https://app.cochat.ai/papers/10.3390/cells12010180
- The paper
- Su, Y., Zhang, T., Lu, J., Qian, L., Fei, Y., Zhang, L., Fan, S., Zhou, J., Tang, J., Chen, H., & Liang, C. (2023). Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response. Cells. https://doi.org/10.3390/cells12010180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.